DNA minor groove alkylating agents structurally related to distamycin A

Bibliography

• ARCAMONE F, PENCO S, OREZZI PG, NICOLELLA V,PIRELLI, A: Structure and synthesis of Distamycin A. Nature (1964) 203:1064–1065.
   PubMed Web of Science ®Google Scholar
• PENCO S, REDAELLI S, ARCAMONE F: Distamicina A.Nota II. Sintesi totale. Gazz. Chim. Ital. (1967) 97:1110–1115.
   Google Scholar
• GREHN L, RAGNARSSON U. Novel efficient total synthesis of antiviral antibiotic Distamycin A. J. Org. Chem. (1981) 46:3492–3497.
   Web of Science ®Google Scholar
• PELTON JG, WEMMER DE: Binding modes of distamycin A with d(CGCAAATTTGCG)2 determined by two-dimensional NMR. J. Am. Chem. Soc. (1990) 112:1393–1399.
   Web of Science ®Google Scholar
• BHATTACHARYAS, THOMAS M: DNA binding propertiesof novel distamycin analogs that lack the leading amide unit at the N-terminus. Biochem. Biophys. Res. Comm. (2000) 267:139–144.
   PubMed Web of Science ®Google Scholar
• WANG W, LOWN JW: Anti-HIV-1 activity of linked lexitropsins. J. Med. Chem. (1992) 35:2890–2897.
   PubMed Web of Science ®Google Scholar
• NEAMATI N, MAZUMDER A, SUNDER S et al: Highly potent synthetic polyamides, bisdistamycins and lexitropsins as inhibitors of human immunodefi-ciency virus Type 1 integrase. Mol. Pharm. (1998) 54:280–290.
   PubMed Web of Science ®Google Scholar
• •First report related to the use of polyamides, such as bidista-mycins, as antiviral agents against HIV-1.
   Google Scholar
• ARCAMONE FM, ANIMATI F, BARBIERI B et al: Synthesis, DNA,- binding properties and antitumor activity of novel, distamycin derivatives. J. Med. Chem. (1989) 32:774–778.
   PubMed Web of Science ®Google Scholar
• ••The paper reports the synthesis and antitumour activity oftallimustine.
   Google Scholar
• D'ALESSIO R, GERONI C, BIASOLI G, PESENTI E, GRANDI M,, MONGELLI N: Structure-activity relationship of novel distamycin A derivatives: synthesis and antitumor activity. Bioorg. Med. Chem. Lett. (1994) 4:1467–1472.
   Web of Science ®Google Scholar
• ••This paper describes the synthesis and biological evaluationof a wide class of distamycin A derivatives tethering different alkylating agents.
   Google Scholar
• VIALLET J, STEWART D, SHEPHERD F et al.: Tallimustineis inactive in patients with previously treated small-cell lung cancer- A Phase II trial of the National Cancer Institute of Canada clinical trials group. Lung Cancer (1996) 15:367–373.
   PubMed Web of Science ®Google Scholar
• BROGGINI M, PONTIN M, OTTOLENGHI S, D'INCALCI M,MONGELLI N, MANTOVANI R: Distamycins inhibit the binding of OTT-1 and NFE-1 transfactors to their conserved DNA elements. Nucleic Acids Res. (1989) 17:1051.
   PubMed Web of Science ®Google Scholar
• BARDOS TJ, DATTA-GUPTA N, HEBBORN P, TRIGGLE DJ:A study of comparative chemical and biological activi-ties of alkylating agents. J. Med. Chem. (1964) 8:167–174.
   Web of Science ®Google Scholar
• •This report has a basic role for the study of the chemical alkylating activities of various types of nitrogen mustards.
   Google Scholar
• COZZI P, BERIA I, BIASOLI G et al.: Novel phenyl nitrogen, mustard and half-mustard derivatives of distamycin A. Bioorg. Med. Chem. Lett. (1997) 7:2985–2990.
   Web of Science ®Google Scholar
• •This paper describes the activities and the structure-activity relationships of novel benzoyl and cinnamoyl nitrogen mustard and half-mustard derivatives of distamycin A.
   Google Scholar
• COZZI P, BERIA I, BIASOLI G et al.: Novel phenyl nitrogen, mustard and half-mustard derivatives of amidino-modified distamycin A. Bioorg. Med. Chem. Lett. (1997) 7:2979–2984.
   Web of Science ®Google Scholar
• •This report describes some amidino-modified derivatives of novel benzoyl and cinnamoyl nitrogen mustard and half-mustard tethered to deformyldistamycin A.
   Google Scholar
• WYATT MD, GARBIRAS BJ, HASKELL MK, LEE M, SOUHAMI RL, HARTLEY JA: Structure-activity relation-ship of a series of nitrogen mustard- and pyrrole-containing minor groove-binding agents related to distamycin. Anti Cancer Drug Design (1994) 9:511–525.
   PubMedGoogle Scholar
• BARALDI PG, COZZI P, GERONI C, MONGELLI N,ROMAGNOLI R, SPALLUTO G: Novel benzoyl nitrogen mustard derivatives of pyrazole analogues of distamycin A: synthesis and antitumor activity. Bioorg. Med. Chem. (1999) 17:251–262.
   Google Scholar
• •This paper describes the synthesis and antitumour activities of benoyl nitrogen mustard derivatives of distamycin A bearing one or more pyrazole replacing the pyrrole rings of the latter.
   Google Scholar
• BARALDI PG, BERIA I, CACCIARI B et al.: Structure- activity, relationship of novel tallimustine derivatives: synthesis and antitumor activity. Bioorg. Med. Chem. Lett. (1996) 6:1247–1252.
   Web of Science ®Google Scholar
• LEE HH, BOYD M, GRAVATT GL, DENNY WA: Pyrazoleanalogues of the bispyrrolecarboxamide anti-tumor antibiotics: syntheses, DNA binding and anti-tumor properties. AntiCancer Drug Design (1991) 6:501–517.
   PubMedGoogle Scholar
• BARALDI PG, ROMAGNOLI R, SPALLUTO G et al: DNAsequence-recognizing properties of minor groove alkylating agents: effects of the replacement of N-methylpyrrole by an N-methylimidazole on tallimustine and its own homologous. Arzneimittel-Forschung/Drug Research (2000) In press.
   Google Scholar
• LEE M, RHODES AL, WYATT MD, D'INCALCI M, FORROWS, HARTLEY JA: In vitro cytotoxicity of GC sequence directed alkylating agents related to distamycin. J. Med. Chem. (1993) 36:863–870.
   PubMed Web of Science ®Google Scholar
• HARTLEY JA, WYATT MD, GARBIRAS BJ, RICHTER BJ, RICHTER C, LEE M: Probing the importance of the second chloroethyl arm of a benzoic acid mustard derivative of an imidazole-containing analogue of distamycin. Biorg. Med. Chem. Lett. (1994) 4:2421–2424.
   Web of Science ®Google Scholar
• XIE G, GUPTA R, LOWN JVV: Design, synthesis, DNAsequence preferential alkylation and biological evaluation of N-mustard derivatives of distamycin and netropsin analogues. AntiCancer Drug Design (1995) 10:389–409.
   PubMedGoogle Scholar
• BARALDI PG, BALBONI G, ROMAGNOLI R et al: PNU 157977: a new potent antitumor agent exhibiting low in vivo toxicity in mice injected with L1210 leukemia cells. AntiCancer Drug Des. (1999) 14:71–76.
   PubMedGoogle Scholar
• ••This paper reports a compound with a high survival time(%T/C).
   Google Scholar
• BARALDI PG, BERTA I, CACCIARI B et al.: Synthesis andantitumor activity of novel distamycin derivatives. Biorg. Med. Chem. Lett. (1996) 6:1241–1246.
   Web of Science ®Google Scholar
• BOGER DL, BOYCE CW, GARBACCIO RM, GOLBERG JA:CC-1065 and the duocarmycins: synthetic studies. Chem. Rev. (1997) 97:787–828.
   PubMed Web of Science ®Google Scholar
• BARALDI PG, CACCIARI B, GUIOTTO A et al.: Design,synthesis and biological activity of pyrrolo [2,1-c][1,4] benzodiazepine (PBD)- distamycin hybrid. Bioorg. & Med. Chem. Lett. (1998) 8:3019–3024.
   PubMed Web of Science ®Google Scholar
• BARALDI P G, CACCIARI B, GUIOTTO A et al.: Synthesis, antiproliferative activity and DNA-binding properties of hybrid molecules containing pyrrolo [2,1-c] [1,4] benzodiazepine (PBD) and minor groove binding oligopyrrole carriers. J. Med. Chem. (1999) 42:5131–5141.
   PubMed Web of Science ®Google Scholar
• ••This paper describes the synthesis of a series of hybridsbetween polypyrrole minor groove binders and PBD.
   Google Scholar
• DAMAYANTHI Y, PRAVEEN REDDY BS, LOWN JW: Design and synthesis of novel pyrrolo [2,1-c][1,4] benzodiazepine-lexitropsin conjugates. J. Org. Chem. (1999) 64:290–292.
   PubMed Web of Science ®Google Scholar
• THURSTON DE, BOSE DS: Synthesis and DNA-interactive pyrrolo [2,1-c ][1,4]benzodiazepines. Chem.Rev. (1994) 94:433–465.
   Web of Science ®Google Scholar